Rein Therapeutics Inc. (RNTX) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Pharmaceuticals 行业. 公司总部位于 Austin, TX, 美国. 现任CEO为 James Brian Windsor.
RNTX 拥有 IPO日期为 2017-06-29, 11 名全职员工, 在 NASDAQ Global Market, 市值为 $45.7M.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
